London
· Delayed Price · Currency is GBP · Price in USD Intellia Therapeutics Statistics
Total Valuation
LON:0JBU has a market cap or net worth of GBP 629.83 million. The enterprise value is 187.18 million.
| Market Cap | 629.83M |
| Enterprise Value | 187.18M |
Important Dates
The last earnings date was Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 103.58M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +11.19% |
| Shares Change (QoQ) | +1.62% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 98.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.86 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.46 |
| EV / Sales | 5.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.63 |
Financial Position
The company has a current ratio of 4.90, with a Debt / Equity ratio of 0.15.
| Current Ratio | 4.90 |
| Quick Ratio | 4.57 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -57.92% and return on invested capital (ROIC) is -33.05%.
| Return on Equity (ROE) | -57.92% |
| Return on Assets (ROA) | -30.12% |
| Return on Invested Capital (ROIC) | -33.05% |
| Return on Capital Employed (ROCE) | -61.94% |
| Revenue Per Employee | 87,518 |
| Profits Per Employee | -1.01M |
| Employee Count | 403 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.60% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -68.60% |
| 50-Day Moving Average | 8.22 |
| 200-Day Moving Average | 14.24 |
| Relative Strength Index (RSI) | 48.54 |
| Average Volume (20 Days) | 9,919 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.98 |
Income Statement
In the last 12 months, LON:0JBU had revenue of GBP 35.27 million and -407.05 million in losses. Loss per share was -4.04.
| Revenue | 35.27M |
| Gross Profit | -323.00M |
| Operating Income | -418.78M |
| Pretax Income | -407.05M |
| Net Income | -407.05M |
| EBITDA | -410.83M |
| EBIT | -418.78M |
| Loss Per Share | -4.04 |
Balance Sheet
The company has 389.90 million in cash and 92.30 million in debt, giving a net cash position of 454.99 million.
| Cash & Cash Equivalents | 389.90M |
| Total Debt | 92.30M |
| Net Cash | 454.99M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 603.65M |
| Book Value Per Share | 5.83 |
| Working Capital | 339.63M |
Cash Flow
In the last 12 months, operating cash flow was -291.91 million and capital expenditures -3.10 million, giving a free cash flow of -295.01 million.
| Operating Cash Flow | -291.91M |
| Capital Expenditures | -3.10M |
| Free Cash Flow | -295.01M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,187.36% |
| Pretax Margin | -1,154.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0JBU does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.19% |
| Shareholder Yield | -11.19% |
| Earnings Yield | -64.63% |
| FCF Yield | -46.84% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0JBU has an Altman Z-Score of 0.79. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.79 |
| Piotroski F-Score | n/a |